115 related articles for article (PubMed ID: 10837019)
1. Tumors arising in DNA mismatch repair-deficient mice show a wide variation in mutation frequency as assessed by a transgenic reporter gene.
Baross-Francis A; Milhausen MK; Andrew SE; Jevon G; Jirik FR
Carcinogenesis; 2000 Jun; 21(6):1259-62. PubMed ID: 10837019
[TBL] [Abstract][Full Text] [Related]
2. Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methy1-6-phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Oncogene; 2001 Sep; 20(42):6066-72. PubMed ID: 11593414
[TBL] [Abstract][Full Text] [Related]
3. Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice.
Andrew SE; Reitmair AH; Fox J; Hsiao L; Francis A; McKinnon M; Mak TW; Jirik FR
Oncogene; 1997 Jul; 15(2):123-9. PubMed ID: 9244348
[TBL] [Abstract][Full Text] [Related]
4. Thymic lymphomas arising in Msh2 deficient mice display a large increase in mutation frequency and an altered mutational spectrum.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Mutat Res; 2002 Mar; 500(1-2):67-74. PubMed ID: 11890935
[TBL] [Abstract][Full Text] [Related]
5. Elevated mutant frequencies and predominance of G:C to A:T transition mutations in Msh6(-/-) small intestinal epithelium.
Mark SC; Sandercock LE; Luchman HA; Baross A; Edelmann W; Jirik FR
Oncogene; 2002 Oct; 21(46):7126-30. PubMed ID: 12370835
[TBL] [Abstract][Full Text] [Related]
6. Tumors of DNA mismatch repair-deficient hosts exhibit dramatic increases in genomic instability.
Baross-Francis A; Andrew SE; Penney JE; Jirik FR
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8739-43. PubMed ID: 9671748
[TBL] [Abstract][Full Text] [Related]
7. Msh2 deficiency increases the mutation frequency in all parts of the mouse colon.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Environ Mol Mutagen; 2002; 40(4):243-50. PubMed ID: 12489114
[TBL] [Abstract][Full Text] [Related]
8. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts.
Andrew SE; Xu XS; Baross-Francis A; Narayanan L; Milhausen K; Liskay RM; Jirik FR; Glazer PM
Carcinogenesis; 2000 Jul; 21(7):1291-5. PubMed ID: 10874005
[TBL] [Abstract][Full Text] [Related]
9. Candidate mutator genes in mismatch repair-deficient thymic lymphomas: no evidence of mutations in the DNA polymerase delta gene.
Campbell MR; Thang TY; Jirik FR; Andrew SE
Carcinogenesis; 2000 Dec; 21(12):2281-5. PubMed ID: 11133819
[TBL] [Abstract][Full Text] [Related]
10. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
11. A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy.
Campbell MR; Nation PN; Andrew SE
Cancer Res; 2005 Apr; 65(7):2626-35. PubMed ID: 15805259
[TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis.
Claij N; van der Wal A; Dekker M; Jansen L; te Riele H
Cancer Res; 2003 May; 63(9):2062-6. PubMed ID: 12727820
[TBL] [Abstract][Full Text] [Related]
13. Mouse mismatch repair gene Msh2 is not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers.
Sonneveld E; Vrieling H; Mullenders LH; van Hoffen A
Oncogene; 2001 Jan; 20(4):538-41. PubMed ID: 11313985
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous and mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells.
Borgdorff V; van Hees-Stuivenberg S; Meijers CM; de Wind N
Mutat Res; 2005 Jul; 574(1-2):50-7. PubMed ID: 15914206
[TBL] [Abstract][Full Text] [Related]
15. Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53/Big Blue double transgenic mice.
Buettner VL; Hill KA; Nishino H; Schaid DJ; Frisk CS; Sommer SS
Oncogene; 1996 Dec; 13(11):2407-13. PubMed ID: 8957082
[TBL] [Abstract][Full Text] [Related]
16. Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice.
Nikitin AY; Liu CY; Flesken-Nikitin A; Chen CF; Chen PL; Lee WH
Cancer Res; 2002 Sep; 62(18):5134-8. PubMed ID: 12234974
[TBL] [Abstract][Full Text] [Related]
17. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
18. Transmission of mutations in the lacI transgene to the offspring of ENU-treated Big Blue male mice.
Barnett LB; Tyl RW; Shane BS; Shelby MD; Lewis SE
Environ Mol Mutagen; 2002; 40(4):251-7. PubMed ID: 12489115
[TBL] [Abstract][Full Text] [Related]
19. 1,3-butadiene: cancer, mutations, and adducts. Part II: Roles of two metabolites of 1,3-butadiene in mediating its in vivo genotoxicity.
Recio L; Saranko CJ; Steen AM
Res Rep Health Eff Inst; 2000 Mar; (92):49-87; discussion 141-9. PubMed ID: 10925839
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice.
Gorelick NJ; Andrews JL; deBoer JG; Young R; Gibson DP; Walker VE
Environ Mol Mutagen; 1999; 34(2-3):154-66. PubMed ID: 10529740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
